Stockwinners Market Radar for May 30, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:21 EDT Berkshire Hathaway acquires 4.66M Occidental shares for $273M - In a regulatory filing, Berkshire Hathaway (BRK.A) disclosed the purchase of 4.66M common shares of Occidental (OXY) in multiple transactions on May 25th through May 30th priced in a range of $58.30-$58.85 per share.

18:45 EDT Riot Platforms CFO sells $549.6K in common stock - In a regulatory filing, Riot Platforms disclosed that its CFO Colin Yee sold 50.3K shares of common stock on May 25th in a total transaction size of $549.6K.

18:28 EDT Knight-Swift executive chairman Knight sells 50,000 class A shares - In a regulatory filing, Knight-Swift executive chairman Kevin Knight disclosed the sale of 50,000 class A common shares of the company on February 2 at a price of $64 per share.

18:23 EDT Marvell CEO: Cloud CapEx spending is moving more towards AI - In an interview on CNBC's Mad Money, Matt Murphy said the sales Marvell are getting from AI are "pretty big." He expects a 100% revenue CAGR from FY23-FY25. There are big opportunities on the custom computing side where Marvell shines, he noted. The company's backlog and revenue outlook has increased significantly in just the past three months, he added.

18:11 EDT Xencor presents clinical results from Phase 1a stufy of XmAb564 - Xencor "announced the presentation of results from its Phase 1a single-ascending dose study of XmAb(R)564 in healthy volunteers. XmAb564 is a potency-tuned IL-2-Fc fusion protein, engineered to selectively activate and expand regulatory T cells for the potential treatment of patients with autoimmune diseases. Results will be presented in a poster titled "XmAb564, a Novel Potency-Tuned IL-2 Fc-Fusion Protein Selectively Expands Regulatory T Cells: Results from a Single Ascending-Dose Study in Healthy Adult Volunteers" at the European Congress of Rheumatology being held May 31 to June 3 in Milan, Italy." CEO Bassil Dahiya states: "We have previously presented that a single dose of XmAb564 was well tolerated in healthy volunteers and generates durable, dose-dependent and selective expansion of regulatory T cells. The magnitude and duration of Treg induction may be superior to other IL-2 candidates evaluated clinically and could potentially support extended multi-week dosing intervals. We continue to enroll patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis, and we anticipate completing dose escalation in psoriasis cohorts in early 2024."

17:52 EDT Chairman of Howard Hughes Bill Ackman buys almost $7M in shares - William Ackman, the Chairman of Howard Hughes Corp, disclosed in a regulatory filing that he had purchased 92,320 shares of company stock at $74.28 per share, between May 25 and May 30, for a total transaction amount of $6,857,290.

17:42 EDT MEI Pharma confirms receipt of an unsolicited and non-binding proposal - MEI Pharma confirmed receipt of an unsolicited and non-binding proposal on May 23 from a group represented by Anson Advisors and Cable Car Capital, as referenced in their 13-D filing of earlier today, to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Company's clinical assets. Consistent with its fiduciary duties, MEI's Board, in consultation with its independent financial and legal advisors, is reviewing the proposal from Anson Advisors and Cable Car Capital and will respond in due course. The board will pursue the course of action it believes is in the best interest of all MEI shareholders. MEI's shareholders are advised that no action is necessary at this time. The recommendation by the MEI Board to proceed with the pending Infinity Pharmaceuticals, transaction remains unchanged.

17:15 EDT Atlantic Coastal Acquisition II receives noncompliance notification from Nasdaq - Atlantic Coastal Acquisition II announced that it had previously received written notification from the listing qualifications department of Nasdaq on May 24 that, because the company had not yet filed its quarterly report on Form 10-Q for the three month period ended March 31 with the SEC, the company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250. The notice has no immediate effect on the listing of the company's securities on Nasdaq. The notice states that the company has 60 calendar days from the date of the notice to provide Nasdaq with a specific plan to achieve and sustain compliance. On May 25, the company filed the 10-Q.

17:11 EDT Ur-Energy announces restart at Lost Creek In Situ Uranium Facility - Ur-Energy announce the successful startup of production flow from Header House 2-4 at Lost Creek In Situ Uranium Facility in Sweetwater County, Wyoming. Production rates will continue to increase as additional header houses in Mine Unit 2 come online this year. Lost Creek production inventory will be sold into remaining 2023 contract book of 180,000 pounds U3O8 in the second half of the year. Beginning in 2024, the Company's total sales quantity under contract is 600,000 pounds U3O8 annually, plus or minus a small, optional flex. The company also announced that construction of our Casper, Wyoming centralized services facility, shown below, is complete and will facilitate full laboratory and construction services for each of our mining projects. The centralized location will allow for reduced drive times and improved safety for our employees while reducing operating costs and increasing efficiencies.

17:04 EDT Clear Channel Outdoor to sell businesses in Italy and Spain for $80.5M - Clear Channel Outdoor Holdings announced agreements to sell its businesses in Italy and Spain to subsidiaries of JCDecaux SE. Gross proceeds from the two separate all-cash transactions total approximately EUR75.1M, or $80.5M. The all-cash consideration represents a combined transaction multiple of approximately 9.62x Segment Adjusted EBITDA contribution based on twelve months ended December 31, 2022, and 7.04x based on twelve months ended March 31. The Company intends to use the anticipated net proceeds from the sales, after payment of transaction-related fees and expenses, to improve its liquidity and increase the financial flexibility of the business, subject to any limitations set forth in its debt agreements. The sale of the Company's business in Italy is expected to close imminently, and the sale of its business in Spain is expected to close in 2024, upon satisfaction of regulatory approval and other customary closing conditions. The Company has hedged the anticipated proceeds from the sale of its business in Spain to mitigate the risks related to foreign currency fluctuations.

17:01 EDT LL Flooring confirms receipt of unsolicited offer from F9 brands - LL Flooring "confirmed that it has received an unsolicited, non-binding proposal from Cabinets To Go, LLC , a subsidiary of F9 Brands, Inc., to acquire all of the outstanding shares of the Company for $5.76 per share in cash. Consistent with its fiduciary duties and in consultation with its financial and legal advisors, the LL Flooring Board of Directors will carefully review and consider the proposal in the context of LL Flooring's strategic plan to determine the course of action that it believes is in the best interests of the Company and all of its shareholders. The Company believes that the long-term fundamentals of LL Flooring's business are strong and believes that it is successfully executing on its six core growth strategies. LL Flooring believes that it is well positioned to take advantage of the medium- to long-term tailwinds for repair and remodel spending, and believes that the Company's unique positioning differentiates it from others in the market."

16:39 EDT Equity Residential raises FY23 same store revenue growth view to 5.5%-6.25% - Prior view was 4.5%-6%. Raises FY23 NOI change to 6%-7% from 4.75%-6.25%. Sees FY23 physical occupancy 96% vs. prior view of 96.2%.

16:35 EDT Freshpet responds to Jana Partners - The company's counsel states: "We write on behalf of our client, Freshpet, Inc. in response to your letter of May 25, 2023 on behalf of JANA Strategic Investments Benchmark Master Fund, L.P. ("JANA"). Your letter contains several erroneous and unfounded claims about the Company's board of directors (the "Board"), the composition of the Board's classes, and the date of the Company's 2023 Annual Meeting of Stockholders. Furthermore, you have omitted information critical to understanding the intent and effect of the Board's actions addressed by your letter. Contrary to your assertions, the Board has acted in the best interests of all stockholders, in accordance with the directors' fiduciary duties, and in compliance with the requirements of the Company's Sixth Amended and Restated Certificate of Incorporation (the "Charter"). Regarding the two primary claims made by your letter: You claim that Charles Norris's upcoming retirement at the 2023 Annual Meeting is "pretext" and intended to reduce the seats subject to election at the 2023 Annual Meeting. In fact, Mr. Norris is not standing for re-election pursuant to the retirement policy adopted by the Board in June 2021. You claim that the Board appointed David Biegger to serve as a director in Class I, rather than Class III, to avoid the need to subject him to an election contest at the 2023 Annual Meeting. In fact, the provisions of the Charter required Mr. Biegger's appointment to Class I. You also reference the date of the 2023 Annual Meeting. Holding the meeting in July is the opposite of entrenchment and did not disadvantage JANA's nomination efforts, which were first publicly disclosed on September 22, 2022, prior to last year's annual meeting. Charles Norris is not seeking re-election due to the Board's age-based retirement policy adopted in June 2021 The announcement of Mr. Norris's upcoming retirement should not have come as a surprise to JANA. The retirement is the result of an age-based retirement policy adopted and publicly disclosed years ago. On August 14, 2020, the Company publicly announced a five-year corporate governance enhancement program. The following slide describing these governance enhancements appeared on page 7 of the Company's 2020 proxy statement, which is available on the Company's investor relations website. Among other changes, the plan contemplated the adoption of a "director retirement policy" in 2021. On June 8, 2021, the Company adopted a director retirement policy pursuant to which non-employee directors who attained the age of 75 would not be nominated for re-election or reappointment to the Board. The director retirement policy was discussed on pages 11 and 12 of the Company's 2021 and 2022 proxy statements, respectively, which are likewise available on the Company's investor relations website. As disclosed in the Company's 2021 proxy statement, Mr. Norris was then 75, and no other director was more than 64. It should have been clear to JANA that the retirement policy would result in Mr. Norris not standing for re-election at the 2023 Annual Meeting. Indeed, as I am confident your client is aware, the prominent event-driven equity research firm Gordon Haskett Research Advisors commented on the retirement policy and its implications in a March 16, 2023 note to subscribers.1 In light of the foregoing, we are skeptical that JANA ever believed that Mr. Norris would stand for re-election at the 2023 Annual Meeting, nor therefore believed that four director seats would be up for election. The Charter required that David Biegger join the Board as a Class I director On May 17, 2023, the Company announced Mr. Biegger's appointment as a Class I director. The terms of the Charter mandated Mr. Biegger's designation as a Class I director. Your assertions that the Board should have done otherwise are meritless. As you acknowledge, the Charter requires that directors "be divided into three classes as nearly equal in size as is practicable, designated Class I, Class II and Class III."2 The Charter further provides that "[if] the number of directors divided into classes as set forth herein is hereafter changed, any newly created directorship(s) . . . shall be so apportioned among the classes as to make all classes as nearly equal in number as practicable."3 Put simply, if the Board had done what JANA now seemingly demands (appointing Mr. Biegger into Class III), the Board would have violated the Charter. This is demonstrated by the below table that sets forth the classification of the Board before and after Mr. Biegger's appointment compared to the classification that JANA apparently prefers. Finally, you suggest in passing that holding the meeting in July, rather than in October, serves to entrench the Board. To the contrary, the change results in the terms of the incumbent directors up for re-election at the 2023 Annual Meeting being shortened by two months, and provides an earlier opportunity for the election of JANA's slate of directors in lieu of incumbent directors. This is the opposite of entrenchment. Further, nothing about this timing disadvantages JANA's nomination efforts. On September 22, 2022, JANA disclosed that it had entered into nomination agreements with three individuals to stand for election at the 2023 Annual Meeting. In fact, JANA's announcement of its potential nominees occurred eleven days prior to last year's Annual Meeting. On December 9, 2022, JANA announced it had entered into a nomination agreement with a fourth candidate. Thus, including Scott Ostfeld (a JANA principal), JANA had five pre-arranged nominees from which to select at the time the Company announced the date of the 2023 Annual Meeting. Indeed, on May 25, 2023, JANA delivered a nomination notice to the Company with a slate of directors chosen from among these individuals. Thus, the notion that JANA's nomination efforts were disadvantaged does not comport with the facts. The Board has acted in the best interests of all stockholders, in accordance with the directors' fiduciary duties, and in compliance with the Charter's requirements. Should JANA decide to challenge these actions or otherwise continue to make ill-informed and baseless accusations, the Company intends to vigorously defend itself and its record."

16:32 EDT Air Industries receives noncompliance notification from NYSE - Air Industries announced that the company received a notice from NYSE regulation stating that the company is not in compliance with the continued listing standards of the NYSE American under the timely filing criteria set forth in Section 1007 of the NYSE American company guide. The non-compliance results from the company's failure to timely file its quarterly report on Form 10-Q for the quarter ended March 31 by the filing due date of May 22, 2023.

16:32 EDT Ambarella falls 13% to $71.47 after Q2 revenue outlook misses estimates

16:31 EDT Mawson Infrastructure to Russell Microcap Index - Mawson Infrastructure is set to join the broad-market Russell Microcap(R) Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.

16:30 EDT SEC settles with former Coinbase manager and his brother over insider trading - The Securities and Exchange Commission announced that former Coinbase product manager Ishan Wahi and his brother, Nikhil Wahi, agreed to settle charges that they engaged in insider trading through a scheme to trade ahead of multiple announcements regarding at least nine crypto asset securities that would be made available for trading on the Coinbase platform. Ishan and Nikhil Wahi each agreed to be permanently enjoined from violating Section 10(b) of the Securities Exchange Act and Rule 10b-5 and to pay disgorgement of ill-gotten gains, plus prejudgment interest. As is often the case when a criminal court has already ordered defendants to forfeit their ill-gotten gains, the disgorgement and prejudgment interest in the SEC's case would be deemed satisfied by the orders of forfeiture of the Wahi brothers' assets in the criminal action, if approved by the court, and the SEC determined not to seek civil penalties in light of the Wahi brothers' prison sentences. The SEC's complaint, filed on July 21 , in the U.S. District Court for the Western District of Washington, alleged that, while employed at Coinbase, Ishan Wahi helped to coordinate the platform's public listing announcements that included what crypto assets would be made available for trading. According to the complaint, Coinbase treated such information as confidential and warned its employees not to trade on the basis of, or tip others with, that information. However, from at least June 2021 to April 2022, in breach of his duties, Ishan repeatedly tipped the timing and content of upcoming listing announcements to his brother, Nikhil Wahi, and his friend, Sameer Ramani. Ahead of those announcements, which usually resulted in an increase in the assets' prices, Nikhil Wahi and Ramani allegedly purchased at least 25 crypto assets, at least nine of which were securities, and then typically sold them shortly after the announcements for a profit. The Wahi brothers agreed, as part of the settlement, not to deny the SEC's allegations."While the technologies at issue in this case may be new, the conduct is not. We allege that Ishan and Nikhil Wahi, respectively, tipped and traded securities based on material nonpublic information, and that's insider trading, pure and simple," said Gurbir S. Grewal, Director of the SEC's Division of Enforcement. "The federal securities laws do not exempt crypto asset securities from the prohibition against insider trading, nor does the SEC. I am grateful to the SEC staff for successfully working to resolve this matter." Reference Link

16:28 EDT F9 tells LL Flooring prepared to consider $5.76 per share buyout offer

16:26 EDT Enzo says attack led to unauthorized access of 2.47M individuals' test info - In a regulatory filing, Enzo Biochem noted that as previously disclosed, on April 6, the company experienced a ransomware attack that impacted certain information technology systems. "In response, the company promptly deployed containment measures, including disconnecting its systems from the internet, launched an investigation with assistance from third-party cybersecurity experts, and notified law enforcement. The company adhered to its disaster recovery plan, which enabled it to maintain operations throughout the incident response process. The company's facilities are open, and it continues to provide services to its patients and partners. On April 11, 2023, the company became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the company's information technology systems as part of this incident. The investigation of this incident and the assessment of its impact is ongoing. However, the company identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. The company is evaluating whether its employees' information may have been involved. The company will provide notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law. The company has incurred, and may continue to incur, certain expenses related to this attack, including expenses to respond to, remediate and investigate this matter. Further, the company remains subject to risks and uncertainties as a result of the incident, including as a result of the data that was accessed or exfiltrated from the company's network as noted above. Additionally, security and privacy incidents have led to, and may continue to lead to, additional regulatory scrutiny. The company is in the process of evaluating the full scope of the costs and related impacts of this incident," the filing stated.

16:23 EDT Ready Capital holders okay stock issuance in deal with Broadmark Realty Capital - Ready Capital announced that at the special meeting of stockholders held conducted by means of a virtual meeting held live over the internet, its stockholders approved the issuance of the Company's common stock pursuant to the terms of the previously announced merger agreement with Broadmark Realty Capital. Pursuant to the merger agreement, Ready Capital will acquire Broadmark through Broadmark's merger with and into a wholly owned subsidiary of Ready Capital. The Merger is expected to close on May 31 subject to customary closing conditions. As a result of the Merger, among other things, each share of common stock of Broadmark outstanding at the effective time of the Merger will be converted into the right to receive from Ready Capital 0.47233 shares of common stock, par value $0.0001 per share, of Ready Capital . Cash will be paid in lieu of fractional shares of Ready Capital Common Stock that would have been received as a result of the Merger. Broadmark also announced that its stockholders have approved the Merger.

16:18 EDT Bristow Group subsidiary selected by the Irish Department of Transport - Bristow Ireland, a subsidiary of Bristow Group, has been announced by the Irish Department of Transport as the preferred bidder for the next Irish Coast Guard, or IRCG, search & rescue aviation, or SAR, contract. The contract will provide for the day and night-time operation of four helicopter bases in Sligo, Shannon, Waterford and Dublin. In addition to the helicopter service, the new Coast Guard aviation service will, for the first time, also include a fixed wing aircraft element.

16:11 EDT PepGen announces clinical hold placed on PGN-EDODM1 IND by FDA - PepGen announced that the company received a clinical hold notice from the FDA regarding their investigational new drug application, or IND, to initiate a Phase 1 study of PGN-EDODM1 in patients with Myotonic Dystrophy Type 1, or DM1. The FDA indicated its intention to provide an official clinical hold letter to PepGen stating the reasons for the clinical hold within 30 days.

16:10 EDT Amazon Web Services announces general availability of Amazon Security Lake - Amazon Web Services announced the general availability of Amazon Security Lake, a service that automatically centralizes an organization's security data from across their AWS environments, leading SaaS providers, on-premises environments, and cloud sources into a purpose-built data lake, so customers can act on security data faster and simplify security data management across hybrid and multicloud environments. Amazon Security Lake converts and conforms incoming security data to the Open Cybersecurity Schema Framework open standard, making it easier for security teams to automatically collect, combine, and analyze security data from more than 80 sources, including AWS, security partners, and analytics providers. Amazon Security Lake is part of a broad set of AWS Cloud security services that build on AWS's secure infrastructure to help make it the most flexible and secure cloud trusted by millions of customers, including some of the most security-sensitive organizations, and is supported by a broad community of security partners to help customers elevate their security in the cloud. Amazon Security Lake aggregates and optimizes large volumes of disparate log and event data to enable faster threat detection, investigation, and response so organizations can effectively address potential issues quickly, using their preferred analytics tools.

16:09 EDT Lantronix CEO Paul Pickle resigns to become CEO of Semtech - Lantronix (LTRX) announced that Paul Pickle will be resigning from his role as president and chief executive officer and as a director of Lantronix to pursue another opportunity as the chief executive officer of Semtech Corporation (SMTC). Pickle's resignation will be effective as of a date yet to be determined, between June 8 and June 29. Until the effective date of his resignation, Pickle will continue in his current officer and director roles while the company conducts a search for a new CEO. If a new CEO has not been appointed by Pickle's last day with the company, the company's chief financial officer, Jeremy Whitaker, will serve as interim chief executive officer of the company until the board of directors appoints a new permanent CEO. MWhitaker also served as the company's interim CEO for brief periods during 2015 and 2019 and will continue to serve as CFO of the company, a position he has held since September 2011.

16:03 EDT Gevo announces Nancy Young as chief sustainability officer - Gevo announced that Nancy Young has been hired as chief sustainability officer to lead the sustainability, environmental, and scientific affairs for the comany. Young is a veteran of the aviation industry, with expertise in developing environmental and sustainability policy, and regulatory programs, as well as in commercial deployment of low carbon fuels and technologies. Her most recent position was as chief sustainability officer for Alder Fuels.

16:02 EDT LatAmGrowth SPAC receives non-compliance letter from NASDAQ - LatAmGrowth SPAC announced that on May 24 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that it was not in compliance with Nasdaq Listing Rule 5250 as a result of it not having timely filed its Quarterly Report on Form 10-Q for the quarter ended March 31 with the SEC. The Nasdaq notification letter provides the Company with 60 calendar days, or until July 24, to submit to Nasdaq a plan to regain compliance in accordance with Nasdaq's listing requirements. The Company does not currently expect submission of a compliance plan will be necessary as it anticipates filing its Q1 10-Q prior to the expiration of the 60 day period. The Company anticipates that it will fully regain compliance with the NASDAQ continued listing requirements upon such filing of its 2023 Q1 10-Q.

16:01 EDT Seres Therapeutics receives $125M milestone payment from Nestle Health Science - Seres Therapeutics "announced that the Company has received a $125 million milestone payment from Nestle Health Science related to the U.S. Food and Drug Administration approval of VOWST, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI. The approval milestone follows the July 2021 agreement between Seres and Nestle Health Science to jointly commercialize VOWST in the U.S. and Canada. Following VOWST commercialization, each company will be entitled to share equally in commercial profits and losses. In addition, Seres is eligible to receive payments of up to $225 million for the achievement of specified net sales milestones."

15:24 EDT Seagen shareholders approve acquisition by Pfizer - Following a special meeting of its stockholders, Seagen (SGEN) announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer (PFE) will acquire Seagen for $229 per share in cash. More than 99% of the shares voted at the meeting, representing approximately 88% of the shares of Seagen common stock issued and outstanding as of the record date for the special meeting, were voted in favor of the proposal to adopt the merger agreement. Subject to the fulfillment of customary closing conditions, including receipt of required regulatory approvals, the acquisition is expected to close in late 2023 or early 2024.

13:00 EDT Wejo Group trading resumes

12:38 EDT Femsa announces EUR 3.3B offering of shares of Heineken - Fomento Economico Mexicano, S.A.B. de C.V., or "Femsa," (FMX) announces an offering by the company and its wholly-owned subsidiaries company Internacional de Bebidas, S.A. de C.V. and Grupo Industrial Emprex, S. de R.L. de C.V. of existing issued ordinary shares of both Heineken N.V. and Heineken Holding N.V. in the total amount of approximately EUR 3.3B, or approximately 5.9% of the combined interest in the Heineken Group. The company also announces today a tap issuance of euro denominated senior unsecured bonds in the aggregate principal amount of up to EUR 250M, exchangeable into ordinary shares of Heineken Holding N.V.. The new bonds will be consolidated and form a single series with the company's EUR 500M 2.625% senior unsecured Exchangeable Bonds due 2026, originally issued on February 24, 2023, effect from on or about July 18, 2023. The offering has been approved by FEMSA's board of directors and is conducted and announced in accordance with applicable law. The equity offering will be executed via an accelerated bookbuild to qualified investors. Investors will have the opportunity to acquire shares in the equity offering in Heineken N.V. and Heineken Holding N.V. The total number of shares to be sold in the equity offering and the selling price per share for each of Heineken N.V. and Heineken Holding N.V. will be determined at pricing subject to a minimum number of 26.4M shares of Heineken N.V. and 8.9M shares of Heineken Holding N.V. L'Arche Green N.V., the entity through which the Heineken Family exercises control of Heineken Holding N.V., is expected to participate in the equity offering for an amount of c. EUR 50M in shares in Heineken Holding N.V. Additionally, Heineken N.V. has committed to purchase a fixed amount equivalent to 10% of Heineken Shares and/or Heineken Holding Shares that will be sold pursuant to the equity offering, subject to certain conditions.

12:29 EDT PS5 game 'Ratchet & Clank: Rift Apart' releasing on PC July 26 - Sony said that 2021 PlayStation 5 title "Ratchet & Clank: Rift Apart" will be arriving on PC July 26, 2023. The release marks the first time a "Ratchet & Clank" game will be available on PC. Reference Link

12:00 EDT Skyline Champion falls -9.7% - Skyline Champion is down -9.7%, or -$6.28 to $58.24.

12:00 EDT Bright Health falls -20.0% - Bright Health is down -20.0%, or -$2.35 to $9.42.

12:00 EDT Equitrans Midstream rises 34.2% - Equitrans Midstream is up 34.2%, or $2.08 to $8.18.

11:09 EDT Siebert Financial appoints John Gebbias as chairman and CEO, effective May 24 - Siebert Financial announced that John J. Gebbia has been appointed as Chairman of the Board and CEO of Siebert, effective May 24, the appointment of Simon Shin to Siebert's Board of Directors, and the close of Kakao Pay's $17.4M investment in Siebert. Shin has been appointed to Siebert's Board of Directors as part of the recently announced investment by Kakao Pay in Siebert. "We are delighted to welcome our new Chairman of the Board and CEO, John J. Gebbia, as well as Mr. Shin to our Board of Directors at a pivotal time in Siebert's growth story," said Gloria E. Gebbia, controlling shareholder and board member of Siebert. "John J. Gebbia has a proven track record and will help Siebert successfully navigate into a new era and thrive going forward. He is a strategic leader with the capability to identify value and deliver impressive results and growth in current and new business lines. Mr. Shin from Kakao Pay is an accomplished executive with global experience and adds significant strength and depth to our Board of Directors. Mr. Shin's extensive fintech experience will be critical in helping Siebert advance to the next era of technology and new offerings for our clients."

11:07 EDT Rackspace Technology awarded cloud cooperative services contract by Texas DIR - Rackspace Technology announced that it has been awarded a new Cloud Cooperative Services contract with the Texas Department of Information Resources Cooperative Contracts Program. The contract provides the State of Texas the ability to purchase Infrastructure as a Service, Platform as a Service, Miscellaneous as a Service, Cloud Broker, and Related Services through a streamlined procurement process and accelerates the delivery of services for Rackspace Technology, the company said. "Since Rackspace Technology has been evaluated, selected and awarded to do business with Texas government entities, public sector customers in Texas will have the ability to procure cloud services without having to go through a public bid process," said Rick Rosenberg, Vice President, and GM of Rackspace Technology Government Solutions.

10:43 EDT BioLight announces joint cooperation agreement with AstraZeneca's Alexion - BioLight reports it has signed a research collaboration agreement with Alexion AstraZeneca Rare Disease focusing on exploring a technology that utilizes natural tears for the potential diagnosis of retinal diseases. "The study, financed by Alexion and BioLight, will evaluate a screening technique that analyzes components of the tear film, an outer eye surface fluid layer. The Technology was licensed from Harvard University and will be utilized to analyze tear samples by one of the inventors, Prof. Yifat Merbl, of the Weizmann Institute of Science. The study will be conducted at the Tel Aviv Medical Center and led by Prof. Anat Loewenstein, Chair of the Ophthalmology department," BioLight announced earlier.

10:14 EDT QuantaSing Group Ltd- ADR trading resumes

10:07 EDT Politan Capital urges Masimo shareholders to vote for Politan nominees - Politan Capital Management, a 9% shareholder of Masimo Corporation, released a presentation "highlighting why independent oversight and greater accountability are urgently needed on the Masimo Board. Politan also responded to multiple false and misleading claims made by the Company in its recent proxy materials and letter to shareholders." The firm said, "Shareholders can support change by voting for Politan's two ideally qualified nominees - Michelle Brennan and Quentin Koffey - for election to the Company's Board at Masimo's Annual Meeting of Stockholders. The Annual Meeting is currently scheduled for June 26, 2023...In its recent proxy materials and letter to shareholders, Masimo makes a number of statements about its own performance and Politan's campaign that Politan believes are disingenuous, false or both: Masimo's cherry picking of dates and peers in an attempt to make its performance look better is 'good for a laugh and not much else.' As one third-party analyst noted in response to Masimo's materials, 'Today's letter takes "cherry picking" to a new level...Team Masimo's plainly obvious attempt to cherry pick data to make the case that its relative returns are unimpeachable...is good for a laugh and not much else.'..Masimo distorts its poor ROIC performance. The Company makes the claim that its ROIC has not declined and that its capital allocation has been "excellent" by skewing the facts. As Politan shows in its own materials, which do adjust for royalties, Masimo's ROIC has decreased by 30% since 2012. Meanwhile, Masimo presents ROIC on an after-tax basis and only through 2021 in order to benefit from a 38% reduction in its effective tax rate due to 2017 tax reform and to ignore another stepdown in ROIC in 2022...Masimo's claims that Politan is seeking "control" of the Company are absurd. ..For over nine months, Masimo's Board has never been willing to meet with Politan. The Company's recent claims that Politan has been unwilling to "engage" or "cooperate" with the Board are simply not credible. If anything, the Board's pattern of engagement has only served to underscore its broken governance."

10:01 EDT ClearSign regains compliance with Nasdaq listing requirements - ClearSign Technologies announced that it has received notice from The Nasdaq Stock Market LLC on May 25 informing ClearSign that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. ClearSign was previously notified on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq. In order to regain compliance with the rule, the company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on May 24, the tenth consecutive trading day above $1.00.

10:00 EDT Bright Health falls -7.6% - Bright Health is down -7.6%, or -89c to $10.88.

10:00 EDT Taro Pharmaceutical rises 24.2% - Taro Pharmaceutical is up 24.2%, or $7.11 to $36.50.

10:00 EDT Arlington Asset Investment rises 47.8% - Arlington Asset Investment is up 47.8%, or $1.32 to $4.07.

09:47 EDT Bright Health falls -10.1% - Bright Health is down -10.1%, or -$1.19 to $10.58.

09:47 EDT Taro Pharmaceutical rises 24.2% - Taro Pharmaceutical is up 24.2%, or $7.12 to $36.51.

09:47 EDT Arlington Asset Investment rises 52.0% - Arlington Asset Investment is up 52.0%, or $1.43 to $4.18.

09:28 EDT Vuzix and Materialise collaborating for 3D eyewear printing technology - Vuzix (VUZI) and Materialise (MTLS) have announced a collaborative effort to accelerate the design and production of smart eyewear using 3D printing technology. By integrating 3D printing into the manufacturing process, Vuzix and Materialise aim to accelerate the development of new innovations for enterprise applications, from warehouses to operating rooms. Vuzix and Materialise will collaborate to accelerate the design and production of smart eyewear

09:27 EDT Applied UV to effect a 1-for-5 reverse stock split on May 31 - Applied UV announced that it will effect a 1-for-5 reverse stock split of its common stock, par value $0.0001 per share . Applied UV's Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "AUVI" and will begin trading on a split-adjusted basis when the market opens on May 31. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 03828V402. The Reverse Stock Split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement.

09:23 EDT Aware brings AwareID to walk network 'A Safer Walk' - Aware is now bringing its adaptive verification platform, AwareID, to A Safer Walk, a verified walk network that connects women with other women so they can accompany one another in public.

09:18 EDT Campbell Soup sells Emerald Nuts to Flagstone Foods - Campbell Soup has sold Emerald Nuts to Flagstone Foods, manufacturer and distributor of private label snack nuts and trail mixes. Flagstone operates three plants, located in Robersonville, North Carolina; El Paso, Texas; and Dothan, Alabama.

09:09 EDT Aurora Innovation set to join the Russell 3000 Index effective June 26 - Aurora Innovation announced that as part of the annual reconstitution of the Russell stock indexes, Aurora is expected to be included in the Russell 3000 Index effective after the U.S. market opens on June 26. A preliminary list of index additions, including Aurora Innovation, was posted by FTSE Russell on May 19. "We are pleased to be included in the Russell 3000 Index, one of the most widely cited performance benchmarks for the U.S. stock market," said Chris Urmson, Co-Founder and CEO at Aurora. "This milestone increases our global visibility, expands our investor base, and highlights the momentum in our path to commercial launch." The Russell 3000 Index encompasses the 3,000 largest U.S.-traded stocks and membership in the Russell 3000 Index means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as in the appropriate growth and value style indexes. Membership in these indexes is updated annually and remains in place for one year.

09:07 EDT PacBio appoints Olga Troyanskaya to Scientific Advisory Board - PacBio appointed Olga Troyanskaya to PacBio's Scientific Advisory Board and Jay Shendure as Chair. Troyanskaya is a Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics. She joined Princeton in 2003 as an assistant professor and became a full professor in 2013. She is also the Deputy Director of Genomics at the Flatiron Institute of the Simons Foundation. Created in Nov. 2022, the SAB provides guidance to the research and development efforts at PacBio, including critical feedback, advice, and expertise on future technological and scientific direction to inform PacBio's priorities and roadmaps for current and future products. Troyanskaya replaces Joseph Puglisi. The next SAB meeting is taking place May 30.

09:06 EDT Wrap Technologies to showcase virtual reality training program, Wrap Reality - Wrap Technologies announced its participation in the upcoming International Counterterrorism Conference, taking place in Las Vegas, Nevada from May 31 to June 2, 2023. During the conference, the Company will showcase its immersive VR training platform, Wrap Reality, featuring modules that address crucial aspects of counterterrorism, including Suicide Bomber Training, Human Trafficking Training, and Weapons Training. "We look forward to demonstrating the world-class capabilities of Wrap Reality at the International Counterterrorism Conference," said Kevin Mullins, CEO of Wrap Technologies. "Our goal is to empower law enforcement and military personnel with the tools and skills they need to mitigate the constantly evolving threats of terrorism. The counterterrorism training modules within Wrap Reality(TM) underscore our commitment to harnessing technology to safeguard communities and improve the effectiveness of security operations worldwide."

09:05 EDT T2 Biosystems announces company's second largest sepsis-driven instrument sale - T2 Biosystems announced the second largest sale of sepsis-driven T2Dx Instruments in Company history. T2 Biosystems' distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx Instruments and sepsis test panels that are expected to be deployed in selected hospitals across Poland. The initial order includes seven T2Dx Instruments, valued at more than $450,000, with the potential for nine additional instruments to be sold and deployed into an increased number of hospitals in Poland during the second half of 2023. The initial term of the contract secured by our distributor is for three years, with the potential to extend for an additional two years. "We are thrilled with this order and look forward to working closely with our distribution partner, Biomedica Poland, to deliver our state-of-the-art sepsis diagnostic products to hospitals across Poland," stated John Sperzel, Chairman and CEO of T2 Biosystems. "Our sepsis test revenue increased by 67% in Central Europe during the first quarter of 2023, compared to the prior year period, and we believe there is enormous potential to further expand the adoption of our sepsis products in Poland and throughout Europe."

09:04 EDT Sotherly Hotels board declares special preferred dividend payable in July - Sotherly Hotels announced that its Board of Directors has authorized payment of a special cash dividend for the Company's Series B, Series C, and Series D Preferred Stock. The Board of Directors authorized, and the Company has declared, a special cash dividend of $0.50 per share of beneficial interest of the Company's 8.0% Series B Cumulative Redeemable Perpetual Preferred Stock. The Series B preferred dividend will be paid on July 14, 2023 to shareholders of record as of June 30, 2023. The Board of Directors also authorized, and the Company has declared, a special cash dividend of $0.4921875 per share of beneficial interest of the Company's 7.875% Series C Cumulative Redeemable Perpetual Preferred Stock. The Series C preferred dividend will be paid on July 14, 2023 to shareholders of record as of June 30, 2023. The Board of Directors also authorized, and the Company has declared, a special cash dividend of $0.515625 per share of beneficial interest of the Company's 8.25% Series D Cumulative Redeemable Perpetual Preferred Stock. The Series D preferred dividend will be paid on July 14, 2023 to shareholders of record as of June 30, 2023.

09:04 EDT GM Defense, Black Sage Technologies sign teaming agreement - GM Defense and Black Sage Technologies announced a teaming agreement to explore the development of a Counter Unmanned Aerial System solution for use on GM Defense military vehicles provided to global defense and government customers at Canadian Association of Defence and Security Industries 2023. The two companies will collaborate on the research, development and market viability of a C-UAS solution, on properties such as the Infantry Squad Vehicle.

09:03 EDT Silo Pharma commences study of novel joint homing peptide SPU-21 - Silo Pharma announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis, designated as SPU-21, in human synovial tissue surrounding joints and tendons. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, "The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue. The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity."

09:03 EDT LPL Financial: Wiser Advisor Group joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Larry Lytle, CFP(R), and Zach Lytle, CEPA(R), have launched an independent practice, Wiser Advisor Group, LLC ("Wiser Advisor"), and joined LPL Financial's broker-dealer, RIA and custodial platforms. The advisors reported having served approximately $130 million in advisory, brokerage and retirement plan assets* and join from RBC Wealth Management. Based in Phoenix, Wiser Advisor was co-founded by managing partners Larry and son Zach. The father-son duo have worked together since 2018 and said their close relationship and shared passion for client success led them to start an independent practice. The advisors focus on three primary service areas: philanthropy and charitable giving, succession planning and individual wealth planning.

09:02 EDT Arthur J. Gallagher cquires Bernard Benefits and Healthcare Financial Planning - Arthur J. Gallagher acquired Nashville, Tennessee-based Bernard Benefits and Bernard Healthcare Financial Planning, subsidiaries of Bernard Health. Terms of the transaction were not disclosed. Bernard Benefits is a health and employee benefits brokerage firm with a focus on small group businesses in Tennessee, Indiana and Texas. Bernard Healthcare Financial Planning advises individuals and families on health insurance coverage. Brian Tolbert, Matt Kleymeyer and their team will remain in their current location under the direction of Robby White, head of Gallagher's South Central region employee benefits consulting and brokerage operations.

09:01 EDT STMicroelectronics introduces MEMS pressure sensor with ten-year longevity - STMicroelectronics has introduced the market's first MEMS water/liquid-proof absolute pressure sensor with a declared 10-year longevity program for the industrial market. ST's new ILPS28QSW sensor comes in a sealed, cylindrical, surface-mountable package. It features a ceramic substrate that provides high resistance to liquid permeability and a robust potting gel, proven in automotive applications, to protect the internal circuitry. The lid, made from high-grade surgical steel, is sealed with an o-ring and secured with epoxy adhesive. This unique package design ensures an ingress-protection rating of IP58 to withstand immersion in over one meter of water, certified according to IEC 60529 and ISO 20653. In addition, the sensor can sustain up to 10Bar over-pressure.

08:50 EDT Camber Energy's Viking announces notice of allowance for U.S. patent - Camber Energy's majority-owned subsidiary, Viking Energy Group announced that Viking's majority-owned subsidiary, Viking Protection Systems received a Notice of Allowance from the United States Patent & Trademark Office for patent application No. 17/693,504 titled "Electric Transmission Line Ground Fault Prevention Systems Using Dual, High Sensitivity Monitoring Devices". A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application. A patent from the recently allowed application is expected to be issued in the coming weeks. The prospective patent relates to Viking Protection's proprietary transmission line ground fault prevention system, which is designed to detect a break in a transmission line, or coupling failure, and to immediately de-energize the line, thus preventing an energized high voltage transmission line from contacting ground or a grounded structure. The technology is designed to be an integral component within a much-needed, worldwide grid hardening and stability initiative by electric utilities to improve resiliency and reliability of existing infrastructure. Viking Protection's software-based solution can be deployed within a utility's existing protective relay infrastructure, allowing the utility to protect its grid with greater confidence and reliability.

08:48 EDT EpicQuest Education renews recruiting agreement with Miami University - EpicQuest Education's wholly owned subsidiary Quest Holding International and Miami University entered into a Memorandum of Agreement for Quest to recruit international students residing outside of the US for admission to the Miami University English Language Center at the Miami University Regional Campuses. The Agreement is for five-years as compared to the previous three-year agreements during the past decade; the current agreement will begin on July 1, 2023 and end on June 30, 2028. EpicQuest Education has a long-term recruitment relationship with the Miami University Regionals for the Middletown and Hamilton campuses which dates back to 2013.

08:46 EDT Nocturne Acquisition receives notice of non-compliance from Nasdaq - Nocturne Acquisition received a second notification on May 24, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market as a result of its failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023, and remaining delinquent in filing its Annual Report on Form 10-K for the period ended December 31, 2022. The Second Notification advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). The Company has since filed its Form 10-K, and is working diligently to complete and file the Form 10-Q as soon as practicable. In accordance with Nasdaq's letter dated April 21, 2023, the Company has until June 20, 2023, to submit a plan to regain compliance with respect to these delinquent reports. Please note that any Staff exception to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or October 16, 2023. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

08:44 EDT U.S. DoD accredits GlobalFoundries to manufacture trusted semiconductors - The U.S. Department of Defense, DoD, through the Defense Microelectronics Activity, DMEA, Trusted Access Program Office, TAPO, has accredited GlobalFoundries' advanced manufacturing facility in Malta, New York, as a Category 1A Trusted Supplier with the ability to manufacture secure semiconductors for a range of critical aerospace and defense applications. The latest milestone in the longstanding partnership between the DoD and GF, the accreditation was enabled by GF's ability to meet DoD requirements for having stringent security processes, equipment, and oversight in place to accept and protect sensitive information and manufacture Trusted chips in a way that ensures they are secure and uncompromised. "The secure manufacturing of semiconductors is critical to safeguarding the confidentiality, integrity, and reliability of the technology that powers our modern world, and nowhere is this more important than aerospace, defense, and critical infrastructure systems," said Dr. Thomas Caulfield, president and CEO of GF. "We are proud to deepen our relationship with the Defense Department, and to receive DMEA accreditation at our New York manufacturing facility. GF's differentiated chip technologies provide optimized performance for critical DoD systems, and we are uniquely positioned by our ability to provide secure semiconductor manufacturing at scale."

08:42 EDT Pyxis Oncology advances PYX-106, PYX-201 clinical programs - Pyxis Oncology announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors. The Company also announced that the second dose level has been initiated in the ongoing Phase 1 trial of PYX-201, a novel antibody-drug conjugate product candidate licensed from Pfizer targeting extradomain-B of fibronectin, a non-internalizing antigen that is an integral component of the extracellular matrix in tumors. "We are excited to announce dosing of the first subject in the Phase 1 trial of PYX-106 and we are enthusiastic about the potential PYX-106 may hold for patients, particularly those not well served by currently available immunotherapies," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "We expect to see preliminary data from each of our ongoing Phase 1 trials of PYX-106 and PYX-201, including biomarker results and potential early signs of clinical activity, in the late-2023 to early-2024 timeframe."

08:41 EDT SAB Biotherapeutics to present at the BIO 2023 International Convention - SAB Biotherapeutics announced that Eddie Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics will present at the BIO 2023 International Convention. The conference, known as the world's largest and most influential event for the pharmaceutical and biotechnology industry, will take place from June 5 to June 8, 2023 at the Boston Convention and Exhibition Center in Boston, Mass. During the presentation, titled "Therapeutic immunoglobulin for pre- and post-exposure prophylaxis and treatment of influenza," Dr. Sullivan will primarily discuss SAB-176, a fully-human polyclonal antibody therapeutic for the treatment of Type A and Type B influenza infections. Dr. Sullivan will present positive clinical data supporting the use of SAB-176 as an effective treatment option for influenza, along with insights into the recent Breakthrough Therapy and Fast Track Designations granted by the U.S. Food and Drug Administration. He will provide a comprehensive overview of SAB's proprietary DiversitAb immunotherapy platform, which utilizes genetically modified bovines, called Transchromosomic Bovin, to produce fully-human hIgG antibodies.

08:40 EDT SeqLL enters definitive merger agreement with Lyneer Staffing Solutions - SeqLL announced that it has entered into a definitive merger agreement with Lyneer Investments, the indirect parent company of Lyneer Staffing Solutions, LLC and Atlantic Acquisition Corp., and related parties, pursuant to which Lyneer will become a wholly-owned subsidiary of SeqLL. Under the terms of the Merger Agreement, SeqLL will pay $60,000,000 in cash to the Lyneer members, and issue to the Lyneer members and Atlantic, an aggregate of 159,866,898 shares of its common stock for all of the membership interests of Lyneer, subject to adjustment for any change in the outstanding shares of capital stock of SeqLL as a result of the prospective reverse stock split and any other stock split, stock dividend, stock distribution, reorganization, recapitalization, reclassification or combination, exchange or readjustment of shares having a record date on or after the date of the Merger Agreement and prior to the consummation of the Merger. Prateek Gattani, the Chairman and CEO of IDC Technologies, Inc., the controlling member of Lyneer, will be appointed Chairman of the Board of SeqLL upon completion. Pursuant to the terms of the Merger Agreement, SeqLL has agreed to file with the Securities and Exchange Commission a registration statement for the offer and sale of approximately $75 million of its common stock, the proceeds of which will be used to pay the $60 million cash consideration in the Merger to the Lyneer members and for working capital of SeqLL post-closing of the Merger. The transactions contemplated by the Merger Agreement are subject to approval by the stockholders of SeqLL. SeqLL has agreed to file a proxy statement on Schedule 14A for the purpose of soliciting proxies from its stockholders for the approval of certain matters with respect to the Merger to be acted upon at a special meeting of such stockholders. Certain officers, directors, and stockholders of SeqLL have entered into a voting agreement pursuant to which such stockholders, who hold a majority of the outstanding shares of SeqLL's common stock, have agreed to vote their shares of the Company's common stock in favor of each of the proposals to be submitted by SeqLL for stockholder approval relating to the Merger. At the time of the Merger, SeqLL common stock held by the current stockholders of SeqLL shall be valued at $12 million, based upon the price per share at which the SeqLL common stock is sold in the Capital Raise. In connection with the closing of the Merger, SeqLL will declare a cash dividend payable to the pre-merger stockholders of SeqLL in an amount equal to the cash on hand as of the closing date of the Merger less withholding taxes and certain other liabilities. Also, the management of Atlantic and Lyneer will become the management of SeqLL, and the existing business operations of SeqLL, including substantially all of the assets and contractual liabilities of SeqLL, will be sold to a newly-formed company affiliated with Daniel Jones, SeqLL's current Chairman of the Board and Chief Executive Officer, for nominal consideration. Lyneer will continue as the surviving entity and as a wholly-owned subsidiary of SeqLL to be renamed Atlantic International Corp. The Boards of Directors of all parties to the Merger Agreement have unanimously approved the Merger. The parties expect the Merger to be consummated in the third quarter of 2023, subject to completion of the Capital Raise and other customary closing conditions.

08:37 EDT Jet Token partners with Vegas Golden Knights, Cirrus Aviation - Jet Token and Cirrus Aviation have announced an official partnership with the Vegas Golden Knights to provide fans the ultimate private aviation experience for away games. Jet.AI's partnership with VGK and Cirrus Aviation features brand exposure on the Vegas Golden Knights website and newsletters. Cirrus Aviation and Jet.AI will also host a Golden Knights Watch Party during the 2023-24 postseason at their hangar in Las Vegas.

08:35 EDT Duck Creek Technologies appoints McCloskey as Chief Operating Officer - Duck Creek Technologies announces the addition of Chris McCloskey to its leadership team as Chief Operating Officer. McCloskey will be instrumental in driving key strategy, operational and transformation initiatives across the entire business, particularly within our customer and professional services organizations. McCloskey joins Duck Creek from Datto, where he was most recently Chief Customer Officer for the cybersecurity and business continuity company.

08:34 EDT Rain Oncology provides update, outlines priorities for milademetan program - Rain Oncology announced an update to its clinical strategy for milademetan, its small molecule inhibitor of the MDM2-p53 complex, to optimize Company resources. The Company is focused on reducing its cash burn with the expectation to extend cash runway to year-end 2026. "We are working diligently, as additional information continues to come in, to analyze and understand the outcomes in the Phase 3 MANTRA study in DD LPS," said Avanish Vellanki, co-founder and chief executive officer of Rain. "It is imperative we understand those outcomes before allocating further capital to the milademetan program, with corporate expenses to be greatly reduced to maximize optionality for Rain. In the near-term, Rain plans to suspend enrollment in our Phase 2 MANTRA-2 basket trial and terminate plans to initiate the planned Phase 1/2 MANTRA-4 combination trial." Strategic Update Summary: Continue evaluation of the totality of the pivotal Phase 3 MANTRA data; Planned data presentation at a medical conference in 4Q 2023; Suspend enrollment of additional patients into the MANTRA-2 MDM2 amplified basket study; Planned MANTRA-2 clinical update at a medical conference in 4Q 2023; Terminate plans for the MANTRA-4 clinical study in patients with CDKN2A-loss, p53 wildtype advanced solid tumors; Evaluate avenues to enhance the pipeline through precision oncology program acquisition; Streamline internal resources to execute on realigned strategy; Reducing full-time employees by approximately 65%, combined with careful workforce management, including employee attrition; Year-end 2023 cash guidance of $75-$80 million, and cash runway to year-end 2026

08:33 EDT TD Holdings establishes mining JV with Achieve Prosper in Indonesia - TD Holdings has signed a partnership agreement with Achieve Prosper, the owner of high-quality gold mines in Indonesia to establish a joint venture in Lombok, Indonesia for mining three local large gold deposits. The JV will engage in exploring, extracting, beneficiating, and selling the gold deposits. The company, AP and local cooperative community will own 80%, 10%, and 10% equity interest of the JV, respectively. The company is responsible for gold exploration, mining, beneficiation, equipment and technology investment, and daily operation, and AP is responsible for handling relevant certificate procedures and coordinating government relations. The JV will focus on three gold mines located in Lombok, an island in Nusa Tenggara Province, Indonesia. Exploration of the mines confirms that these three mines have abundant gold resources and relatively low extraction difficulties.

08:32 EDT TTEC Holdings opens new customer experience delivery center in Honduras - TTEC Holdings announced the opening of a new customer experience delivery center in Honduras. TTEC is now able to provide digitally-enabled CX services for clients from a new site in San Pedro Sula and will bring hundreds of jobs to the region. The new Honduras customer experience delivery center can serve clients across a wide range of industries.

08:25 EDT Tingo Group's DMCC commences delivery of significant pipeline of export orders - Tingo announced that its export business, operated through wholly owned subsidiary Tingo DMCC, has completed its first batch of export deals, generating $348M of sales with a gross profit approaching $100M. The sales completed are part of an anticipated long-term multi-billion-dollar pipeline of export transactions, more than $1 billion of which are currently being processed for expected delivery by the third quarter of 2023. Having focused on developing a strategic partnership with Prime Commodity Exchange Limited and the All Farmers Association of Nigeria, which, as announced on April 26, 2023, includes exclusive use of AFAN's existing nationwide network of warehouses and the right of first refusal to purchase or trade all produce stored in the warehouses, Tingo Mobile and Tingo DMCC have established a strong foundation and infrastructure from which to procure, handle and deliver several billion dollars per annum of agricultural produce. Darren Mercer, Chief Executive Officer of Tingo, commented: "The commencement and ramp-up of the Tingo DMCC export business, together with its impact on our dollarization and globalization, is a momentous event for us. The management teams of Tingo Mobile and Tingo DMCC have worked together tirelessly to develop and establish a robust and highly scalable supply chain and infrastructure, including through our recently signed strategic partnership with AFAN and PCX, to enable us to target several billion dollars of agricultural produce per annum. This strong foundation gives us confidence in our ability to execute the additional export opportunities we are currently progressing."

08:22 EDT AUM Biosciences doses first patient in Phase 2 trial of AUM001 - AUM Biosciences announced that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer, MSS CRC. "Dosing the first patient in AUM001's Phase 2 trial is a major milestone in advancing our mission to build an industry-leading portfolio of innovative therapies designed to reverse cancer resistance," said Vishal Doshi, Chairman and CEO of AUM. "While colorectal cancer is the third most common cancer globally, there are limited therapeutic options due to the resistance associated with current treatments. AUM is leveraging multi-faceted strategies, technologies, and targets to develop a diversified pipeline of candidates that have distinct mechanisms of action to overcome cancer drug resistance." This randomized and open-label Phase 2 study is designed to evaluate the safety, tolerability, and effectiveness of AUM001 as a monotherapy and in combination with KEYTRUDA, Merck (MRK), with a focus on the microsatellite stable subset. Module 1 is expected to enroll up to forty-eight patients, and top line readout from Module 1 is anticipated in the fourth quarter of 2023. AUM entered into a definitive business combination agreement with Mountain Crest Acquisition Corp. V. (MCAG).

08:20 EDT PrairieSky Royalty receives TSX approval for renewed normal course issuer bid - PrairieSky Royalty announced that the Toronto Stock Exchange has accepted the notice of PrairieSky's intention to commence a normal course issuer bid. On April 17, 2023, PrairieSky announced its intention to seek TSX approval to renew its NCIB for an additional one-year period. The NCIB allows the Company to purchase up to 16,624,000 common shares which represents 7.0% of the common shares outstanding, being 238,916,940 as of May 26, 2023, and 10% of the public float of 166,424,841 common shares which is defined as the common shares outstanding after excluding common shares beneficially owned by directors and executive officers of PrairieSky and persons who beneficially own or exercise control or direction over more than 10% of the issued and outstanding common shares of PrairieSky. The NCIB will commence on June 1, 2023 and will expire no later than May 31, 2024. Under the NCIB, common shares may be repurchased in open market transactions on the TSX, and/or other Canadian alternative trading platforms. In accordance with the rules of the TSX governing normal course issuer bids, the total number of common shares the Company is permitted to purchase is subject to a daily purchase limit of 129,317 common shares, representing 25% of the average daily trading volume of common shares on the TSX calculated for the six-month period ended April 30, 2023, being approximately 517,270 common shares. However, the Company may make one block purchase per calendar week which exceeds the daily repurchase restriction. Any common shares that are purchased under the NCIB will be cancelled upon their purchase by PrairieSky. PrairieSky currently intends to purchase up to a maximum of 16,624,000 common shares to effect NCIB purchases over the next 12 months through its broker BMO Nesbitt Burns Inc. PrairieSky did not purchase any common shares under its current normal course issuer bid that commenced on May 26, 2022 and ran to May 25, 2023. Since instituting the normal course issuer bid in 2016 to March 31, 2023, PrairieSky has purchased and cancelled an aggregate of 16.7 million common shares at a weighted average price per share of $14.77. The Company believes that from time to time the market price of the Common Shares may not reflect their underlying value. The purchase of Common Shares will increase the proportion of interest of, and be advantageous to, all remaining shareholders. In addition, any purchases by the Company will afford increased liquidity to those shareholders of the Company who may wish to dispose of their Common Shares.

08:17 EDT Establishment Labs announces CE mark for the Motiva Injector - Establishment Labs Holdings announced it has received CE marking under the European Medical Device Regulation for the Motiva Injector , the Motiva Inflatable Balloon, and the Motiva Channel Dissector. "The approval in Europe of our minimally invasive tools is an important step in the evolution of plastic surgery," said Juan Jose Chacon-Quiros, Founder and Chief Executive Officer. "Innovations that improve both the experience and outcome of a medical procedure can expand markets. This minimally invasive technology platform can help change perceptions and overcome reservations - opening aesthetics to the many women who would not consider a traditional surgery. We are also extremely gratified that all Motiva implants and tools have now received certification under the new European MDR standard." The Motiva Channel Dissector, Balloon, and Injector are designed to be used in Establishment Labs' next generation minimally invasive aesthetic procedures. Establishment Labs has now completed a full transition of all currently marketed Motiva implants and tools as well as the Company's quality management systems to be in compliance with the new European Medical Device Regulation .

08:17 EDT Teledyne DALSA announces production of Linea 2 4k Multispectral 5gigE camera - Teledyne DALSA announced that its Linea 2 4k Multispectral 5GigE line scan camera is now in production. This new camera takes vision systems to the next level with its performance and value, offering a 5GigE interface with five times the bandwidth of the Linea GigE camera. The Linea2 4k Multispectral 5GigE simultaneously captures high resolution RGB plus Near Infrared multispectral images to reveal invisible features that cannot be detected using visible lighting alone. This makes it ideal for identifying hard to see defects, contaminants and security features in applications such as automated optical inspection, printing inspection, optical sorting systems, material grading and inspection, web inspection and many other machine vision applications.

08:14 EDT Smart for Life announces exercise of warrants for $4.5M in gross proceeds - Smart for Life announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 3,513,750 shares of common stock of the Company issued by the Company on July 1, 2021 and August 18, 2021, each having an exercise price of $2.59 per share, at a reduced exercise price of $1.30 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.5 million, prior to deducting placement agent fees and estimated offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the exercising holders will receive new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable into an aggregate of up to 7,027,500 shares of common stock, at an exercise price of $2.17 per share and have a term of exercise equal to five and one-half years. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

08:12 EDT Amylyx informed that CHMP is trending toward a negative opinion on AMX0035 MAA - Amylyx announced an update on the ongoing review of its Marketing Authorization Application, or MAA, for AMX0035 for the treatment of adults with amyotrophic lateral sclerosis, or ALS, by the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA. Following an oral explanation held at the May meeting of the CHMP, Amylyx was informed that the CHMP is trending toward a negative opinion on the application for conditional marketing authorization of AMX0035. The CHMP is expected to adopt a formal opinion on the MAA at its next meeting, which will be held June 19-22. If a negative opinion is received in June, the company intends to request a formal re-examination of the opinion, which is an approximately four-month process.

08:11 EDT Imunon presents PlaCCine preclinical data at 2023 Viruses and Cells - IMUNON announces that Khursheed Anwer, Ph.D., the company's Executive Vice President and Chief Science Officer, presented new PlaCCine preclinical data at the 2023 Viruses and Cells - Gordon Research Conference in Barcelona. Dr. Khursheed's presentation, titled "A Novel DNA Vaccine Approach to Prophylactic and Therapeutic Vaccines," was delivered on May 25, 2023, and described IMUNON'S PlaCCine technology platform for the development of next-generation vaccines. Results from preclinical studies in a PlaCCine COVID-19 vaccine demonstrated characteristics that address the limitations of current commercial vaccines by offering enhanced breadth of protection to emerging variants, persistence and robust cellular immunity, as well as stability at workable temperatures. Importantly, humoral immune responses specific to the SARS-CoV-2 spike antigen were persistent over a 14-month post-vaccination period in mice, while the T-cell responses from PlaCCine COVID-19 vaccines after 14 months were higher than a commercial mRNA vaccine. In another mouse study, the humoral response to a single dose of a commercial mRNA vaccine plateaued within 14 days after vaccination while the response continued to increase over time with a PlaCCine vaccine, demonstrating improved durability. In addition, PlaCCine was stable for at least eight months at refrigerated temperatures and for at least one month at room temperature.

08:10 EDT Worksport to hold second job fair at NY facility - Worksport announces that it will hold a second Job Fair at its new state-of-the-art U.S. automotive accessory factory at 2500 North America Drive, West Seneca, N.Y., from 11 a.m. to 5 p.m. on Tuesday, June 6. At this wholly owned 220,000 sq. ft facility, the Company is getting ready to produce its advanced hard-folding tonneau covers for the multi-billion-dollar light truck market. "Our first job fair was so successful in retaining at least ten new key employees that the Company is seeking to fill additional important positions with this second job fair," said Worksport CEO Steven Rossi. "With the completion of our state-of-the-art factory in sight, our goal is to staff the facility with high-quality employees from the Western New York area. We intend to make a positive contribution to the local economy as we meet the increasing market demand for our innovative products. Join us as we make history!"

08:09 EDT ProSomnus announces presentation of four abstracts at 2023 AADSM meeting - ProSomnus announced the presentation of four abstracts at the 2023 American Academy of Dental Sleep Medicine, AADSM, Annual Meeting, held May 19-21 in Philadelphia, Pennsylvania, and two abstracts at the American Thoracic Society, ATS, 2023 International Conference, held May 19-24 in Washington, D.C. The data presented at both meetings demonstrate that ProSomnus's Precision OAT devices are: An efficacious first-line treatment for moderate and severe obstructive sleep apnea, characterized by excellent adherence and patient preference relative to CPAP; an efficacious option relative to traditional OAT devices, for all severities of OSA; associated with significantly fewer adverse event reports than CPAP and hypoglossal nerve stimulation treatments. Data from the First Line Obstructive Sleep Apnea Treatment Study study, a clinical trial comparing the clinical effectiveness of OAT and CPAP were presented at both meetings: AADSM: Comparison of Clinical Effectiveness And Patients' Preference for Two Non-invasive Treatment Options for Patients Diagnosed with Moderate to Severe Obstructive Sleep Apnea: The FLOSAT Study; ATS: Oral Appliance Therapy as First-line Treatment Option in Patients Diagnosed With Moderate to Severe Obstructive Sleep Apnea; Overall, patients' apnea-hypopnea index decreased from 22.9 events per hour to 8.0 with OAT. 100% of patients adhered to OAT, while 83% of patients adhered to CPAP. 56.5% of patients preferred OAT, while 34.7% preferred CPAP and 8.8% expressed no preference. In addition, key findings were also presented in the following posters at AADSM: OAT Device Designs are Not the Same When It Comes to FDA Adverse Event Reports; Materials: 98.5% of AERs involved OATs made from lab materials, while just 1.5% involved devices made from engineered materials, such as Medical-grade Class VI polymers. Structure: 98% of AERs involved OATs with metal, elastomeric or nylon components, while just 2% involved monolithic structures. Titration Mechanisms: 93.8% of AERs involved OATs with anterior clasps, Herbst mechanisms and pull mechanisms, while just 6.2% involved 70-degree Dorsal posts or 90-degree twin posts. Liners: 98.5% of AERs involved lab-formed OATs with and without liners, while just 1.5% of AERs involved precision-engineered liner-less devices. Adverse Event Reports for Continuous Positive Airway Pressure, Hypoglossal Nerve Stimulation and Oral Appliance Therapy Devices: an FDA MAUDE Database Analysis; In 2020, there were 126 AERs for CPAP, 445 for HNS and just 24 for OAT. In 2021, there were 6,074 AERs for CPAP, 6,806 for HNS and just 49 for OAT. In 2022, there were 90,923 AERs for CPAP, 23,951 for HNS and just 40 for OAT. Precision vs. Traditional Oral Appliance Therapy: A Comparison of Efficacy; Median efficacy for Precision OAT in individuals with mild to moderate OSA was 92%, while that of Traditional OAT was 75%. Median efficacy for Precision OAT in individuals with severe OSA was 59%, while that of Traditional OAT was 50%.

08:07 EDT Satixfy Communications appoints Nir Barkan as acting CEO - SatixFy Communications announced that Mr. Nir Barkan has been appointed Acting Chief Executive Officer of SatixFy by the Company's Board of Directors effective June 1 replacing the current CEO, Mr. Ido Gur who is stepping down. Nir Barkan previously served as SatixFy's Chief Commercial Officer from 2014 until 2018. Prior to rejoining SatixFy, from 2018 to 2023, Mr. Barkan was a Co-Founder, Group CTO and the General Manager as well as a Director of Curvalux, a company operating in the field of sustainable fixed wireless broadband technology. Prior to Curvalux, Mr. Barkan served as a Satcom Product Marketing Manager at Orbit Communication Systems, as a Director of Marketing, Pre-Sale and Support at Novelsat and other senior roles.

08:06 EDT ReTo Eco-Solutions regains compliance with Nasdaq bid price requirement - ReTo Eco-Solutions received a notification letter from Nasdaq confirming the company has regained compliance with Nasdaq's minimum bid price requirement under its Listing Rules and this matter is now closed.

08:05 EDT Guardion Health Sciences appoints Hall as President, CEO - Guardion Health Sciences announced that Janet Hall has been appointed as the Company's new President and Chief Executive Officer. Hall is assuming these executive positions from Bret Scholtes, who has served in those positions since January 6, 2021. Scholtes is resigning effective June 9, 2023, and is also concurrently resigning from the Board of Directors of the Company. Hall will be officially starting with Guardion on June 19, 2023. Most recently, Jan was Chief Executive Officer of M2 Ingredients.

08:03 EDT Nano Dimension to host conference call on special tender offer for Stratasys - As previously announced, Nano Dimension (NNDM) will host a conference call on Tuesday, May 30th, 2023 at 9:00 a.m. EDT to discuss its special tender offer to increase its ownership in Stratasys Ltd. (SSYS), as well as the merits of Stratasys' proposed deal with Desktop Metal, (DM) which are being positioned as an alternative to the Company's aforementioned special tender offer. On May 25, 2023, the Company commenced a special tender offer to purchase between 38.8% and 40.8% of the outstanding ordinary shares of Stratasys for $18.00 per share in cash, less any required withholding taxes and without interest. The successful completion of the special tender offer would result in Nano Dimension's beneficial ownership of between 53% and 55% of the outstanding Stratasys shares, inclusive of the approximately 14.2% of Stratasys' outstanding ordinary shares that Nano Dimension currently owns. As previously announced, in conjunction with the special tender offer, Nano Dimension also released an investor presentation further detailing the benefits of the special tender offer to Stratasys' shareholders and the strategic rationale for the tender offer, which was filed as an exhibit to the tender offer statement filed with the U.S. Securities and Exchange Commission by the Company on Schedule TO on May 25, 2023, and which can also be accessed on the investor relations page of Nano Dimension's website. During the investor call, shareholders and markets stakeholders will also learn more about the alternative to Nano Dimension's special tender offer - the Stratasys and Desktop Metal deal that was announced on May 25th, 2023. Nano Dimension will articulate the aspects of the SSYS-DM deal that are problematic from a shareholder's perspective, especially in comparison to the certain all-cash value of Nano Dimension's $18.00 per share offer.

08:02 EDT Uber, Serve Robotics announce partnership - Serve Robotics unveiled the scope of their partnership with Uber Technologies. The company's commercial agreement allows for Serve to deploy its robots on Uber Eats in multiple markets across the United States, with up to two thousand Serve Robots to be fielded. Utilizing delivery robots has the potential to reduce traffic congestion and air pollution, while also improving the efficiency of last mile delivery and offering customers and merchants a new and innovative delivery experience. Expanding the partnership with Uber is a significant opportunity for Serve. Serve's robotic deliveries have grown over 30% month over month since deliveries began in 2022, with over 200 restaurants in Los Angeles now participating. This growing awareness and interest in robotic delivery in one of the largest North American markets is evident in the thousands of positive ratings received for completed deliveries.

07:51 EDT Ormat Technologies resumes operation at Heber 1 power plant - Ormat Technologies announced the successful resumption of operations at the Heber 1 power plant in California. This achievement comes after the plant temporarily shut down due to a fire incident that occurred in February 2022. This significant milestone is a testament to Ormat's operational execution and its commitment to providing reliable and sustainable energy solutions to communities in California. In Nevada, Ormat completed a 6MW upgrade to the Dixie Valley power plant, which allows the Company to maximize its favorable long-term power purchase agreement. The upgrade involved the replacement of pre-acquisition equipment with Ormat's state-of-the-art energy converters.

07:38 EDT Skyharbour signs option agreement with North Shore Energy Metals - Skyharbour Resources entered into an option agreement with North Shore Energy Metals which provides North Shore an earn-in option to acquire an initial 80% interest and up to a 100% interest in the South Falcon Property located in Saskatchewan, Canada. The Property contains eleven mineral claims, comprising approximately 42,908 hectares. The Agreement provides North Shore an opportunity to earn an initial 80% interest in the claims over a three year period by fulfilling combined cash, share issuance and exploration expenditure commitments of CAD $5.3 million, with an option to purchase the remaining 20% for an additional CAD $10 million in cash and shares. Pursuant to the Agreement, North Shore may acquire an initial 80% interest in the Property by issuing common shares of North Shore having an aggregate value of CAD $1,225,000; making aggregate cash payments of CAD $525,000; and incurring an aggregate of CAD $3,550,000 in exploration expenditures on the Property over a three-year period.Once North Shore has earned an initial 80% interest in the Property, North Shore may acquire the remaining 20% interest in the Property within 90 business days by issuing Shares having a value of CAD $5,000,000, and making a cash payment of CAD $5,000,000 to Skyharbour. If North Shore does not elect to acquire the remaining 20% interest, a joint venture will be formed with Skyharbour holding a 20% participating interest. North Shore will be the operator of the exploration programs during the earn-in stage and for the joint venture if formed. Two claims totaling 10,673 hectares that form part of Skyharbour's Foster River Property are subject to a one percent NSR royalty payable to Skyharbour. The remaining nine claims totaling 32,235 hectares that comprise Skyharbour's South Falcon Point Property are subject to a two percent NSR royalty payable to Denison Mines with North Shore having the right to purchase one percent of the royalty from Denison at anytime by paying $1 million.

07:35 EDT Akebia receives response from FDA on path forward for vadadustat submission - Akebia received a written response from the FDA's Office of New Drugs - OND - to Akebia's Formal Dispute Resolution Request - FDRR - regarding the Complete Response Letter - CRL - received in March 2022 for vadadustat. The letter from the OND stated the company's appeal was denied; however, the letter provided a path forward for the company to resubmit the new drug application for vadadustat for the treatment of anemia due to chronic kidney disease for dialysis dependent patients. While not dismissing the potential safety signal, the OND indicated that the extent of the increase in potential risk is not large and it may be a reasonable conclusion that the increase in VAT events can be managed as a labeling issue. The CRL noted a concern about the risk for drug-induced liver injury - DILI - and concern that ongoing monitoring would be less uniformly implemented once commercially available than in the clinical trial. The OND concluded that while DILI remains a concern, the DILI signal appears modest in intensity and is potentially manageable with appropriate monitoring. The OND letter states that commercial experience would be highly valuable in considering that DILI can be handled through labeling and that DILI will be an unusual event post-approval. It further advises that data from commercial experience in Japan may prove valuable in further assessing the risk of DILI. Accordingly, Akebia plans to include post-approval data from Japan in the NDA resubmission, where tens of thousands of Japanese patients with CKD have been exposed to vadadustat to date. Notably, based on the safety data the company has received from its partner in Japan, Mitsubishi Tanabe Pharma Corporation, there have been no reports of DILI in the more than two years that vadadustat has been in the market in Japan. The OND suggested that Akebia request a Type A meeting with the Division to ensure alignment on the contents of the NDA resubmission. Akebia plans to request this meeting as soon as possible and expects to resubmit the NDA in the second half of 2023. A launch of Vafseo is expected in Europe by the end of 2023.

07:34 EDT Stronghold Digital Mining reaches hash rate of 3.0 EH/s - The company said, "Over Memorial Day weekend, Stronghold's Bitcoin mining operations achieved a hash rate of 3.0 EH/s. Stronghold achieved this milestone approximately one month earlier than expected. Of the 3.0 EH/s, approximately 80% is wholly owned by the Company and not subject to a profit share. During the second half of May 2023, the Company received the 5,000 MicroBT Whatsminer M50 Bitcoin mining rigs related to its previously announced miner purchase. This was in addition to the initial 2,000 Avalon 1246 Bitcoin mining rigs associated with the Company's previously announced Canaan Bitcoin Mining Agreement that were delivered in early May. Stronghold expects to receive the remaining 2,000 Avalon 1346 Bitcoin mining rigs pursuant to the Canaan Bitcoin Mining Agreement in June 2023. During May 2023, Stronghold expects to earn over 220 Bitcoin through its mining operations, a sequential increase of approximately 23% from its 179 Bitcoin mined during April 2023. The Company continues to actively evaluate incremental opportunities, representing over 1 EH/s, to fill its remaining data center slots. While no assurances can be made that Stronghold will be able to consummate any of these transactions, the Company continues to believe that it will be able to fill its existing 4 EH/s of data center capacity by the end of the third quarter of 2023. Beyond the 4 EH/s of data center capacity at the Company's wholly owned Scrubgrass and Panther Creek plants, Stronghold is also currently evaluating opportunities to deploy its additional 25 MW of end-to-end data center equipment that it owns in inventory. This includes 20 proprietary StrongBox containers and the transformers, breakers, and switchgear to support them."

07:33 EDT Canopy Growth, Indiva announce license assignment, assumption agreement - Canopy Growth and Indiva announced that they have entered into a license assignment and assumption agreement providing Canopy Growth exclusive rights and interests to manufacture, distribute, and sell Wana branded products in Canada which accelerates Canopy Growth's ability to leverage the Wana brand. Simultaneously, to support continuity of quality supply and aligned to Canopy Growth's asset light strategy for sourcing of cannabis 2.0 formats, Canopy Growth and Indiva also entered into a contract manufacturing agreement, under which Canopy Growth will grant Indiva the exclusive right to manufacture and supply Wana branded products in Canada for a period of five years, with the ability to renew for an additional five-year term upon mutual agreement of the parties.

07:28 EDT Alterity Therapeutics initiates second Phase 2 study of ATH434 - Alterity Therapeutics has commenced a new Phase 2 clinical trial of ATH434 in patients with Multiple System Atrophy and the first patient has been enrolled. This open label study, entitled "A Biomarker Study of ATH434 in Participants with MSA" is in addition to the ongoing, randomized, double-blind, placebo-controlled Phase 2 trial in early-stage MSA. The Biomarker trial will enroll approximately 15 individuals with more advanced MSA than those participating in the randomized trial. A key aim of the study is to assess the efficacy of ATH434 on objective biomarkers that measure target engagement and are relevant to the underlying pathology of disease. Clinical measures important in MSA will also be assessed. ATH434-202 study participants will receive treatment with ATH434 for 12-months. The study will assess the effect of ATH434 treatment on neuroimaging and protein biomarkers to evaluate target engagement, in addition to clinical measures, safety, and pharmacokinetics. The selected biomarkers, including brain iron and aggregating alpha-synuclein, are important contributors to MSA pathology and are appropriate targets to demonstrate drug activity. The primary objective of this study is to evaluate the impact of 12 months treatment with ATH434 on brain iron by MRI in a more advanced patient population than is being studied in Alterity's randomized Phase 2 trial.

07:16 EDT Zentek, Pattern Energy collaborate on icephobic technology for wind turbine - Zentek announced a collaboration with Pattern Energy Group to optimize, test and validate Zentek's icephobic coating for the wind turbine industry. The partnership is being supported financially by both the Natural Sciences and Engineering Research Council of Canada and PRIMA Quebec - Advanced Materials Moving Forward. As part of their collaboration, Zentek has agreed to give Pattern Energy a priority position to purchase Zentek's icephobic coating if demand for the product exceeds supply. Zentek has also agreed to give a 40% discount to Pattern on its initial purchases until it has recovered its cost in supporting this research.

07:15 EDT Protalix CEO issues letter to shareholders - Protalix announced the following letter from its president and CEO, Dror Bashan, to its stockholders and the investment community. "As we arrive at the halfway point of this remarkable year, I would like to take a moment to celebrate our success, as well as share our excitement for the future of Protalix. The spring commenced with a bang. Elfabrio(R), our primary development candidate, has been approved for the treatment of adult patients with Fabry disease, both in the United States and the European Union. These approvals mark a significant milestone in our history. Although we faced challenges during our path toward regulatory approval, our team persevered, and you with us. These approvals are a true testament to our commitment to delivering innovative solutions to patients in need. Elfabrio is the second approved therapy based on our proprietary ProCellEx(R) plant cell-based protein expression system, a unique platform conceived of and developed by Protalix and brought to fruition by the talented scientists making up our team. ProCellEx represents a relatively new method for developing recombinant proteins in an industrial-scale manner. Elelyso(R), our first approved drug product, was the first protein produced through plant cell-based expression in suspension to be approved by the FDA. Chiesi Global Rare Diseases, our commercial partner for Elfabrio, is well prepared for a successful commercial launch, and I have every confidence that they will realize the full potential of this much needed therapeutic option. I would like to extend my heartfelt gratitude to Chiesi. Now that we stand on the other side of this accomplishment, we are turning our attention to our pipeline programs which have shown potential for growth. We are excited to focus on these development programs, armed with the knowledge gained from our hard-earned experiences. We plan to share our insights and future strategic initiatives with you and extend an invitation for you to join us at our upcoming in-person investors event on June 27, 2023 at 8:00 am ET at the Lotte Palace Hotel in New York City. Additional details and registration information will soon be available on our website. We are profoundly grateful for your confidence in our company and for standing by us throughout the years. We are excited about the path ahead and the opportunity to connect with you during the upcoming event where we will discuss our future plans that we are designing to drive Protalix's growth. With your continued support, we will work towards a fruitful future, creating value for you, our investors and, most importantly, for patients and their families."

07:12 EDT Contango Ore to join Russell 3000 index - Contango Ore announced that, according to a preliminary list of additions posted on May 19, Contango is set to join the broad-market Russell 3000 and Russell Microcap Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26.

07:11 EDT PyroGenesis signs contract for five metric tons of titanium metal powder - PyroGenesis Canada announces that the Company has received a signed order for five metric tonnes, or 5,000 kg, of its plasma atomized titanium metal powders for 3D printing. In addition, a down payment has been received. The client is an advanced materials company in the United States. For clarity, this client is unrelated to the global aerospace OEM client for which the Company continues the qualification process to become an approved supplier. Additionally, this new client has placed a provisional order for a further six tonnes, contingent upon the client determining, at its discretion, the appropriate demand for additional powders. "With a goal to produce the highest quality metal powders in the additive manufacturing industry, PyroGenesis Additive has taken a cautious, methodical approach towards commercialization of its powders as we designed, then readied, our new NexGen(TM) plasma atomization process," continued Mr. Dattilo. "As mentioned in our previous releases, we started with sample batches for key customers measured in dozens of grams, then progressed to small commercial orders of 100kg each, with the stated goal to then move up to commercial production and sales "By-The-Tonne". This has now been achieved with this multi tonne order."

07:10 EDT C4 Therapeutics, Betta enter exclusive licensing agreement for CFT8919 - C4 Therapeutics and Betta Pharmaceuticals announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China. CFT8919 is an orally bioavailable BiDAC degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer patients. Under the terms of the agreement, C4T expects to receive $35 million, which includes $10 million in upfront cash as well as a $25 million one-time equity investment, to be completed following the receipt of required regulatory approvals and other customary closing conditions. Additionally, C4T is eligible for up to $357 million in potential milestones and low to mid-double-digit percent royalties on net sales in the licensed territories. Betta will be responsible for the development, manufacturing and commercialization of CFT8919 in the licensed territories and is eligible to receive low single-digit percent royalties on net sales outside of Greater China. C4T retains the right to develop and commercialize CFT8919 in all territories outside of Greater China. In preclinical studies, CFT8919 is active in in vitro and in vivo models of EGFR L858R driven NSCLC with broad coverage of on-target resistant mutations and intracranial activity, with the potential to prevent or treat brain metastases in these patients. CFT8919 has been designed to bind to an allosteric site, which is uniquely created by the L858R activating mutation, allowing for exquisite selectivity for this mutation. Further, CFT8919 was designed to be effective independent of secondary EGFR mutations, for example T790M and/or C797S. Additionally, CFT8919 demonstrated potent anti-proliferation activity against a panel of cell lines harboring either L858R single mutation or L858R with additional EGFR mutations that confer resistance to approved EGFR inhibitors such as osimertinib or erlotinib, while sparing cell lines with wild-type EGFR. C4T is on track to submit an Investigational New Drug application to the United States Food and Drug Administration for CFT8919 for the treatment of NSCLC in the first half of 2023.

07:09 EDT Tilray's SweetWater Brewing launches SweetWater Spirits - SweetWater Brewing Company, subsidiary of Tilray Brands, announces the launch of SweetWater Spirits, a new collection of bright and refreshing ready-to-drink mixed cocktails in a can. "The ready-to-drink cocktail category is witnessing rapid growth, and we are thrilled to introduce the new SweetWater Spirits line," said Ty Gilmore, President, U.S. Beer at Tilray Brands. "We have crafted delicious and refreshing low-calorie cocktails using premium vodka, ensuring a sensory experience that surpasses expectations."

07:08 EDT Resolute Forest selling Thunder Bay pulp and paper mill - Resolute Forest has entered into an asset purchase agreement to sell its Thunder Bay, Ontario, pulp and paper mill to an affiliate of Atlas Holdings. The transaction, expected to close in the second half of the year, is subject to the satisfaction or waiver of closing conditions, including obtaining required regulatory approvals. Resolute will continue to operate its sawmills and woodlands operations in Northwestern Ontario. At the closing of the transaction, Resolute will continue to provide chips and biomass to the Thunder Bay mill. The sale of the Thunder Bay mill is a requirement under the consent agreement entered into between Domtar Corporation and the Canadian Commissioner of Competition and registered with the Canadian Competition Tribunal in connection with its review of Domtar's recent acquisition of Resolute.

07:06 EDT Atea Pharmaceuticals board rejects unsolicited proposal from Tang Capital - Atea Pharmaceuticals announced that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea's programs. After careful review and consideration with its independent financial and legal advisors, the Atea Board of Directors unanimously concluded that the Proposal fundamentally undervalues the Company and is not in the best interests of Atea or its shareholders.

07:05 EDT Diebold signs debt restructuring agreement with key stakeholders - Diebold has entered into a restructuring support agreement with certain of its key financial stakeholders to effectuate a comprehensive debt restructuring transaction. The restructuring is expected to significantly reduce debt and leverage levels and provide substantial additional liquidity to support ongoing operations and establish a long-term, sustainable capital structure for the company. The company will continue to pay vendors and suppliers through the expected restructuring process. The company has entered into this agreement with creditors who hold a significant majority of the company's outstanding secured term loan debt and secured notes, including approximately 80.4% of the company's superpriority credit facility; 79% of first lien term loan; approximately 78% of first lien notes; and approximately 58.3% of second lien notes. The restructuring support agreement provides that the Debtors will seek approval of a $1.25 billion debtor-in-possession term loan credit facility (the "DIP Facility") as part of the chapter 11 cases. The proceeds of the DIP Facility will be used to repay in full all obligations under the company's superpriority credit facility; repay in full the company's asset-based revolving credit ABL facility; pay costs and reasonable and documented out-of-pocket fees and expenses related to the court-supervised restructuring proceedings; and fund the working capital needs and expenditures of the Debtors and their non-debtor affiliates during the pendency of the court supervised restructuring proceedings. The Company expects the restructuring transactions to be consummated in Q3. The terms of the restructuring support agreement contemplate that the common shares of the restructured company will be listed on the NYSE.

07:05 EDT Veeva, Lotus Clinical Research expand partnership - Veeva Systems announced that Lotus Clinical Research expanded its partnership with Veeva and broadened its adoption of Veeva Vault Clinical Suite, a strategic move to strengthen its service delivery and efficiency. This builds on Lotus' existing use of Vault Clinical Suite to implement swifter and more connected studies. The successful incorporation of Veeva Vault CDMS, Veeva Vault eTMF, and Veeva Vault CTMS has effectively scaled Lotus' trial operations while sustaining the highest quality standards. With a unified clinical ecosystem, Lotus has significantly reduced study startup time.

07:04 EDT Trevena announces near-term milestones - The Company also reaffirmed expected timing of its many near-term milestones: TRV045 Target Engagement Study. Topline data from the clinical proof-of-concept study, expected 3Q 2023; TRV045 Transcranial Magnetic Stimulation Study. Topline data from the clinical proof-of-concept study, expected 3Q 2023; OLINVYK New Respiratory Data and Additional Health Utilization and Cost Analyses. Data and analyses from ~200 patient real-world clinical outcomes study, expected mid-2023; $3M Nhwa Milestone. Receipt of $3 million milestone payment for OLINVYK regulatory approval in China from Jiangsu Nhwa Pharmaceuticals, expected 2Q 2023; $15M R-Bridge Tranche. $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale of OLINVYK in China, which Nhwa expects 3Q 2023

07:03 EDT Plus Therapeutics announces results from recurrent glioblastoma analysis - Plus Therapeutic announced that a new analysis from its partner Medidata, a Dassault Systemes company, was accepted for online publication at the 2023 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place June 2-6, in Chicago, Illinois. The abstract titled, "Clinical characterization of patients with recurrent glioblastoma in trials involving CED and non-CED treatment," included data sourced from Medidata's more than 30,000 clinical trials involving more than nine million de-identified participants. Aggregate summary statistics comparing bevacizumab and convection-enhanced delivery patients were based on combined study-level and patient-level data using sample size weighted means, incidence and overall survival. "The purpose of this analysis was to determine whether bevacizumab patients could form an appropriate external control for evaluating overall survival in current and upcoming CED trials," said Norman LaFrance, M.D., Chief Medical Officer of Plus Therapeutics. "The results of this analysis provide confidence in the use of an external control arm formed from aggregated clinical trial data of patients previously treated with bevacizumab to interpret the results of the ReSPECT-GBM Phase 1/2 trials. Thus far, our clinical outcomes are promising compared to those using an external control. In a potential future pivotal trial, the use of a historical control arm will enable Plus Therapeutics to more rapidly enroll the trial while simultaneously reducing trial costs."

07:01 EDT Bristol-Myers' repotrectinib application in lung cancer accepted by FDA - Bristol Myers announced that the FDA has accepted the New Drug Application for repotrectinib, a next-generation tyrosine kinase inhibitor, for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, based on results from the TRIDENT-1 trial. The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act goal date of November 27. In the trial, repotrectinib demonstrated high response rates and clinically meaningful durability of benefit in both TKI-naive and TKI-pretreated patients. The safety profile of repotrectinib was well characterized and manageable.

06:47 EDT Team regains NYSE compliance - Team announced that it has received formal notice from the New York Stock Exchange that the company has regained compliance with the NYSE's quantitative continued listing standards.

06:31 EDT SpringsWorks Therapeutics says Phase 2 nirogacestat trial fully enrolled - SpringWorks Therapeutics announced that it has achieved full enrollment in its Phase 2 trial evaluating nirogacestat, an investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors. SpringWorks expects to report initial data from the trial in 2024.

06:07 EDT Gardiner Healthcare Acquisitions receives noncompliance notification from Nasdaq - Gardiner Healthcare Acquisitions announced that it received a notice on May 23 from Nasdaq stating that the company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250 because the company has not yet filed its quarterly report on Form 10-Q for the period ended March 31 with the Securities and Exchange Commission.

06:05 EDT Anew Medical to become public through Redwoods Acquisition merger - Anew Medical announced that it has entered into a definitive merger agreement with Redwoods Acquisition (RWOD). Anew currently has its common stock quoted on the OTC Markets under the symbol (LEAS). The transaction values the combined company at a pro forma enterprise value of approximately $94M with existing Anew stockholders rolling over 100% of their equity into the combined company. Anew stockholders will be eligible to receive additional shares pursuant to an earn-out based on the combined company's stock performance following the closing of the transaction. The transaction is expected to provide approximately $54M of cash proceeds, assuming no redemptions by Redwoods stockholders. These values exclude up to five million of additional earn-out shares that would be issued to Anew stockholders if applicable stock performance-based requirements are met. Upon completion of the transaction, the combined company will operate as Anew Medical and expects to remain listed on Nasdaq.

06:03 EDT AppLovin's Array solutions extends global partnership with OPPO smart devices - AppLovin's Array suite of solutions for OEMs and telecom carriers has broadened its strategic partnership with OPPO, a global smart device brand. The companies are providing OPPO device users with on-device experiences and app recommendations when searching for and downloading apps. Array will also be providing its technology and access to AppLovin's app ecosystem.

05:45 EDT Accenture announces intent to acquire Green Domus Desenvolvimento Sustentavel - Accenture has announced its intent to acquire Green Domus Desenvolvimento Sustentavel LTDA, a Brazil-based sustainability consultancy with experience helping clients design and implement a range of sustainability services with a focus on measurable decarbonization strategies. Green Domus will join Accenture to further enhance its Sustainability Services team. Financial terms of the transaction are not being disclosed.

05:32 EDT Guardant Health granted regulatory approval of Guardant360 CDx - Guardant Health has granted regulatory approval of Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, or CGP, in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor, or EGFR, alterations who may benefit from treatment with Tagrisso.

05:13 EDT Parker-Hannifin awarded five-year Army contract - Parker Aerospace, a business segment of Parker Hannifin, announced an agreement with the U.S. Army for a five-year contract providing overhaul and upgrade to the UH-60 Blackhawk hydraulic pump and flight control actuation. The agreement includes provisions for firm-fixed price, or FFP, indefinite delivery indefinite quantity for the Army's aircraft. Under the sustainment agreement, Parker Aerospace will provide supply chain, engineering and field service support at Corpus Christi Army Depot in Texas under fixed rates.

05:05 EDT BHP Group, Microsoft enter copper recovery collaboration - A new collaboration between BHP (BHP) and Microsoft (MSFT) has used artificial intelligence and machine learning with the aim of improving copper recovery at the world's largest copper mine. The use of new digital technology to optimize concentrator performance at BHP's Escondida operation in Chile is expected to improve copper recovery.